Secukinumab vs Upadacitinib for Axial Spondyloarthritis

This trial tests two treatments, Secukinumab and Upadacitinib, for individuals with axial spondyloarthritis (axSpA), a type of arthritis affecting the spine and pelvis. Researchers aim to evaluate the effectiveness of each treatment after 16 weeks, assess their safety, and determine adherence levels. This trial targets those who have previously tried at least one tumor necrosis factor-alpha inhibitor without success and continue to experience active symptoms impacting daily life. Participants should not have used Secukinumab or Upadacitinib before. As a Phase 4 trial, these treatments have already received FDA approval and demonstrated effectiveness, and this research seeks to understand how they benefit more patients.

Research has shown that both secukinumab and upadacitinib are generally well-tolerated by patients with axial spondyloarthritis, a type of arthritis affecting the spine.

For secukinumab, studies indicate long-term safety, with consistent results across many trials. Patients using secukinumab for up to five years have not reported new safety issues. This treatment effectively improves symptoms and is approved for similar conditions, suggesting its safety.

Upadacitinib also shows promising safety results. Studies report it is well-tolerated, with no new safety risks found in recent trials. However, there is a warning about increased risks of serious infections and other conditions. Despite this, many patients tolerate it well, and it effectively reduces symptoms.

Researchers are excited about these treatments for axial spondyloarthritis because they offer unique approaches compared to standard options like NSAIDs, TNF inhibitors, and physical therapy. Secukinumab is distinctive because it targets the IL-17 pathway, which plays a significant role in inflammation, offering a different mechanism from the commonly used TNF inhibitors. Upadacitinib, on the other hand, is a JAK inhibitor that interrupts specific enzyme pathways involved in the inflammatory process, potentially providing relief with an oral administration rather than injections. These innovative mechanisms of action could lead to more effective and convenient treatment options for patients.

This trial will compare Secukinumab and Upadacitinib for treating axial spondyloarthritis (axSpA). Research has shown that Secukinumab, which participants in this trial may receive, can help treat axSpA. In studies, patients' symptoms improved over time, with 61.5% experiencing significant improvement after six months. Another study found that Secukinumab led to a 40% improvement in symptoms at both 16 and 52 weeks.